Calcium polycarbophil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Calcium polycarbophil
Accession Number
DB14684  (DBSALT002736)
Type
Small Molecule
Groups
Approved
Description

Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.

Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Synonyms
  • Calcium polycarbophil
  • Polycarbophil calcium
  • Polycarbophil, calcium
Active Moieties
NameKindUNIICASInChI Key
CalciumsaltSY7Q814VUP7440-70-2OYPRJOBELJOOCE-UHFFFAOYSA-N
PolycarbophilsaltW25LM17A4W9003-97-8Not applicable
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Best ChoiceTablet, film coated625 mg/1OralBest Choice (Valu Merchandisers Company)2019-04-16Not applicableUs
Calcium Polycarbophil 625 mgTablet625 mg/1OralRemedy Repack2016-10-062018-10-11Us
Calcium Polycarbophil 625 mgTablet625 mg/1OralReliable 1 Laboratories2015-11-01Not applicableUs
Calcium Polycarbophil 625 mgTablet625 mg/1OralREMEDYREPACK INC.2018-10-05Not applicableUs
Care One FiberTablet, film coated625 mg/1OralAmerican Sales Company2004-03-302013-02-22Us
Equalactin - Tab 625mgTablet625 mgOralNumark Laboratories, Inc.1996-12-312009-07-31Canada
Equalactin LaxativeTablet625 mg/1OralNumark Brands, Inc1986-11-21Not applicableUs
Equate fiber therapyTablet, film coated625 mg/1OralWalmart Stores1996-11-052015-11-19Us
FiberTablet, film coated625 mg/1OralWestern Family Foods1998-01-192016-12-08Us
Fiber CapletsTablet625 mg/1Oralbryant ranch prepack2016-06-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
8F049NKY49
CAS number
126040-58-2

Pharmacology

Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Pharmacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateCalcium polycarbophil can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Calcium polycarbophil.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Calcium polycarbophil.
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium polycarbophil.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Calcium polycarbophil.
AcetyldigitoxinCalcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AcetyldigoxinCalcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.
AclidiniumThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Agmatine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [PubMed:6765389]
  2. Monograph [Link]
  3. webmd [Link]
External Links
Wikipedia
Polycarbophil_calcium
ATC Codes
A06AC08 — Polycarbophil calcium
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral625 mg
TabletOral500 mg/1
Tablet, film coatedOral625 mg/1
TabletOral625 mg/1
CapsuleOral625 mg/1
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on September 05, 2018 20:00 / Updated on July 16, 2019 06:23